Welcome to our dedicated page for Enzon Pharma SEC filings (Ticker: ENZN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enzon Pharmaceuticals, Inc. (ENZN) files a range of documents with the U.S. Securities and Exchange Commission that are central to understanding its role as a public company acquisition vehicle and its proposed merger with Viskase Companies, Inc. On this page, you can review Enzon’s Form 8-K current reports, which detail material events such as the execution of the Agreement and Plan of Merger, subsequent amendments to that agreement, and changes to its Section 382 Rights Agreement.
Merger-related 8-K filings describe the structure of the all-stock transaction in which Viskase will merge with and into a wholly owned Enzon subsidiary, the exchange ratios between Viskase common stock, Enzon common stock, and Enzon’s Series C Non-Convertible Redeemable Preferred Stock, and the anticipated post-merger ownership split, including the expectation that current Viskase stockholders will own 55% of the combined company following the amended merger terms. These filings also outline requirements such as a 1-for-100 reverse stock split of Enzon common stock and the role of Icahn Enterprises Holdings L.P. and its affiliates under a support agreement.
Other key filings relate to Enzon’s Section 382 Rights Agreement. Through multiple amendments reported on Form 8-K, Enzon has adjusted the Final Expiration Date of the rights issued under this agreement. The company notes that these amendments are intended to revise the expiration date while leaving the rest of the agreement unchanged, and that management believes the revised dates are in the best interests of stockholders.
Enzon has also stated that it intends to file a registration statement on Form S-4 in connection with the Viskase merger. That filing is expected to contain a consent solicitation statement and prospectus and to include financial information about the combined company. On this page, AI-powered tools can help summarize lengthy filings, highlight key transaction terms, and make it easier to understand complex documents such as merger agreements, rights agreements, and related exhibits.
Enzon Pharmaceuticals amended its Section 382 Rights Agreement and implemented a 1-for-100 reverse stock split. The Eleventh Amendment moves the Final Expiration Date of the Rights Agreement to noon, New York City time, on March 26, 2026. The Reverse Stock Split became effective at 4:30 p.m. ET on March 24, 2026, and Enzon’s common stock is expected to trade on an adjusted basis on the OTCQB at market open on March 25, 2026, under the temporary symbol ENZND for 20 trading days. No fractional shares will be issued; holders entitled to fractions will receive cash payments. The Reverse Stock Split must be completed prior to the contemplated merger with Viskase Companies, Inc.
Enzon Pharmaceuticals, Inc. approved an Eleventh Amendment to its Section 382 Rights Agreement, moving the rights’ Final Expiration Date to noon, New York City time, on March 26, 2026, with no other changes to the agreement.
The company also implemented a previously approved 1-for-100 reverse stock split, effective at 4:30 p.m. Eastern on March 24, 2026. Every 100 shares of common stock are being combined into 1 share, with the par value unchanged and fractional holdings settled in cash. Enzon’s common stock is expected to begin trading on a split-adjusted basis on the OTCQB on March 25, 2026 under the temporary symbol “ENZND” for 20 trading days. The reverse split was completed to make authorized shares available for the anticipated merger with Viskase Companies, Inc. and related common stock issuances in an outstanding exchange offer.
Enzon Pharmaceuticals announced an extension of its exchange offer for holders of Series C Non-Convertible Redeemable Preferred Stock to exchange those shares for Enzon common stock. The Offer now expires at 5:00 p.m. Eastern on March 24, 2026, unless further extended.
The filing also reiterates that Enzon and Viskase Companies, Inc. have a proposed merger and that a Form S-4 registration statement containing a prospectus, consent solicitation statement and offer to exchange has been filed and is available on www.sec.gov and Enzon’s website.
Enzon Pharmaceuticals, Inc. announced that it has extended the expiration date of its exchange offer for shares of its Series C Non-Convertible Redeemable Preferred Stock to 5:00 p.m. Eastern time on March 24, 2026. The offer lets holders swap preferred shares for Enzon common stock.
The exchange offer is part of a broader set of proposed transactions between Enzon and Viskase Companies, Inc., which are described in a previously filed Form S-4 registration statement containing a prospectus, consent solicitation statement and offer to exchange for the combined company.
Enzon Pharmaceuticals amended its Schedule TO to announce an extension of its exchange offer for Series C Non-Convertible Redeemable Preferred Stock. The offer now expires at 5:00 p.m., Eastern Time, on March 24, 2026. The exchange ratio is the aggregate liquidation preference per share divided by $7.83 after giving effect to the Reverse Stock Split.
As of 5:00 p.m., Eastern Time, on March 18, 2026, a total of 339 shares had been validly tendered and not withdrawn, representing <1% of the 40,000 shares outstanding as of March 18, 2026. Holders who already tendered need not re-tender; all procedural documents are incorporated by reference.
Enzon Pharmaceuticals, Inc. entered into the Tenth Amendment to its Section 382 Rights Agreement to extend the Final Expiration Date of the rights from noon, New York City time, on March 18, 2026 to noon, New York City time, on March 24, 2026.
Except for this adjustment to the Final Expiration Date, the Rights Agreement remains unmodified.
Enzon Pharmaceuticals, Inc. reported that it entered into a Tenth Amendment to its Section 382 Rights Agreement, extending the Final Expiration Date of the rights from noon, New York City time, on March 18, 2026 to noon, New York City time, on March 24, 2026.
Management states that this new March 24, 2026 expiration is believed to be in the best interests of the company and its stockholders. Apart from the new Final Expiration Date, all other terms of the Rights Agreement remain unchanged.
Enzon Pharmaceuticals announced an extension of its exchange offer for holders of Series C Non-Convertible Redeemable Preferred Stock to exchange into Enzon common stock; the Offer now expires at 5:00 p.m. Eastern on March 19, 2026, unless further extended.
The filing also reiterates that Enzon filed a Form S-4 registration statement in connection with the proposed merger with Viskase Companies, Inc., which contains a prospectus, consent solicitation statement and offer to exchange; the Registration Statement and related documents are available on the SEC website and Enzon’s website.
Enzon Pharmaceuticals reported that it has extended the expiration date of its exchange offer to holders of Series C Non-Convertible Redeemable Preferred Stock, who are being offered Enzon common stock in exchange for their preferred shares. The offer now expires at 5:00 p.m. Eastern time on March 19, 2026, unless further extended.
This exchange offer is part of a broader proposed transaction between Enzon and Viskase Companies, Inc., for which Enzon has filed a Form S-4 registration statement containing a combined prospectus, consent solicitation statement and offer to exchange. The filing also reiterates extensive forward-looking risk factors that could affect completion and outcomes of the proposed merger and the combined company.
Enzon Pharmaceuticals amended its Schedule TO to report results and extend its exchange Offer for Series C Non-Convertible Redeemable Preferred Stock. The Offer exchanges each share of Series C Preferred Stock for Common Stock using the liquidation preference divided by $7.83 after the Reverse Stock Split.
Enzon extended the Offer expiration to 5:00 p.m. Eastern Time on March 19, 2026. The Depositary reported that as of 5:00 p.m. ET on March 13, 2026, 342 shares had been validly tendered and not withdrawn, representing less than 1% of 40,000 shares outstanding.